NCT01920984View on ClinicalTrials.gov

Vitreous Levels of Cysteine-rich 61 in Patients With Proliferative Diabetic Retinopathy

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
Proliferative Diabetic Retinopathy
Interventions
DRUG

intravitreal injection of 1.25 mg of bevacizumab

Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy

Trial Locations (1)

100

Department of Ophthalmology, National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER

NCT01920984 - Vitreous Levels of Cysteine-rich 61 in Patients With Proliferative Diabetic Retinopathy | Biotech Hunter | Biotech Hunter